Category

News
Wellington End of Year Function Date for 2022 to be advised. It is a requirement to be double vaccinated to attend this event.
Continue Reading
By Selina Wellbelove – 15 Nov 2021 Vaccinated patients with blood cancers experiencing breakthrough COVID-19 infections remain at high risk for severe or critical disease and death, new research shows. Furthermore, it was found that patients with lymphomas were more at risk than those with other haematological malignancies. The study, led by Dr Livio Pagano,...
Continue Reading
A study showing fatigue is common and enduring in non-Hodgkin lymphoma (NHL) survivors has highlighted the need for more proactive screening and management in blood cancer patients, an Australian occupational therapist says. The US study, which assessed fatigue’s prevalence and persistence in 555 NHL survivors, found it occurred in more than a quarter of patients at...
Continue Reading
Nichola Oakenfull is partially vaccinated against Covid-19, but she’s still scared. The Wellington woman was diagnosed with multiple myeloma (a type of blood cancer) during alert level 3 last year – a diagnosis that may reduce the efficacy of the Pfizer vaccine. “It is very scary because I’m doing as much as I can to try and keep myself safe, but you are relying...
Continue Reading
This Phase I trial is now open at Middlemore Hospital in Auckland for t (11,14 ) RRMM patients.
Continue Reading
This article originally published on The Limbic Most parents of children undergoing active cancer treatment at the RCH Children’s Cancer Centre, Melbourne last year reported no change to their child’s care due to COVID-19. An online survey of more than 100 parents in October-November 2020 found 69% reported no change to their child’s treatment plan...
Continue Reading
Pomalidomide (Pomalyst) in combination with bortezomib and dexamethasone (PVd) will be reimbursed on the PBS from 1 October for patients with relapsed or refractory  multiple myeloma who have received at least one prior treatment regimen including lenalidomide. According to distributor Bristol Myers Squibb, the thalidomide analogue was approved based on findings from the OPTIMISMM trial...
Continue Reading
People with blood cancers who are immunocompromised are now advised to have a third primary dose of COVID-19 vaccine with an mRNA vaccine. On 8 October the Australian Technical Advisory Group on Immunisation (ATAGI) recommended a booster third dose of vaccine as part of the primary course in individuals who are severely immunocompromised to address the risk...
Continue Reading
This article was originally posted on Stuff Around 21,000 Kiwis are living with blood cancer. Symptoms can be difficult to recognise, and experts worry that some people aren’t getting diagnosed as our health system tackles the impact of Covid-19. Hayley McLarin investigates. Neil Brownlie has beaten blood cancer three times in a decade. The former...
Continue Reading
Welcome to issue 39 of Multiple Myeloma Research Review. This issue’s selection includes research reporting that switching elderly intermediate-fit patients with MM to reduced-dose lenalidomide maintenance without dexamethasone after nine cycles of Rd was both feasible and provided outcomes similar to those associated with continuing Rd. As usual we have attached the PDF, and now...
Continue Reading
1 2 3 4 5 35

Floor 7, 90 The Terrace
Wellington Central
New Zealand